CRANBURY, N.J., Aug. 3, 2011 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the 31st Annual Canaccord Genuity Growth Conference in Boston, MA on Wednesday, August 10 at 1:00 p.m. ET.
A live webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 90 days. Participants are encouraged to visit the web site 10 minutes prior to the start of the presentation to register, download and install any necessary software.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare diseases. The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration. Amicus' lead program Amigal™ (migalastat HCl) is in Phase 3 for the treatment of Fabry disease.
CONTACT: Amicus Therapeutics
Source: Amicus Therapeutics, Inc.
News Provided by Acquire Media